These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38949295)

  • 1. The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes.
    Riley DR; Hydes T; Hernadez G; Zhao SS; Alam U; Cuthbertson DJ
    Liver Int; 2024 Oct; 44(10):2538-2550. PubMed ID: 38949295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term risk of cardiovascular disease associated with MASLD and different cardiometabolic risk factors in IBD patients: A prospective cohort study.
    Zhang Q; Xu F; Liu S; Zhu S; Zhang S; Wu J; Wu S
    Liver Int; 2024 Sep; 44(9):2315-2328. PubMed ID: 38819640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019.
    Danpanichkul P; Suparan K; Dutta P; Kaeosri C; Sukphutanan B; Pang Y; Kulthamrongsri N; Jaisa-Aad M; Ng CH; Teng M; Nakano M; Morishita A; Alkhouri N; Yang JD; Chen VL; Kim D; Fallon MB; Diaz LA; Arab JP; Mantzoros CS; Noureddin M; Lazarus JV; Wijarnpreecha K
    Metabolism; 2024 Sep; 158():155958. PubMed ID: 38942169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease.
    Kjeldsen SAS; Werge MP; Grandt J; Richter MM; Thing M; Hetland LE; Rashu EB; Jensen AH; Winther-Sørensen M; Kellemann JS; Holst JJ; Junker AE; Serizawa RR; Vyberg M; Gluud LL; Wewer Albrechtsen NJ
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G558-G570. PubMed ID: 39104323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease.
    Shen TH; Aby ES; Vock D; Farley JF
    Diabetes Obes Metab; 2024 Nov; 26(11):5116-5125. PubMed ID: 39134463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.
    Elsaid MI; Li N; Firkins SA; Rustgi VK; Paskett ED; Acharya C; Reddy KR; Chiang CW; Mumtaz K
    Aliment Pharmacol Ther; 2024 May; 59(9):1096-1110. PubMed ID: 38538967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.
    Xiao L; Li Y; Hong C; Ma P; Zhu H; Cui H; Zou X; Wang J; Li R; He J; Liang S; Li Z; Zeng L; Liu L
    J Transl Med; 2024 Jul; 22(1):650. PubMed ID: 38997780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis.
    Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
    Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):351-358. PubMed ID: 38407898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction-associated steatotic liver disease and risk of esophageal cancer in patients with diabetes mellitus: a nationwide cohort study.
    Jeon YJ; Han K; Lee SW; Lee JE; Park J; Cho IY; Cho JH; Shin DW
    Dis Esophagus; 2024 Jul; 37(8):. PubMed ID: 38587429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Targher G; Byrne CD; Tilg H
    Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
    Mao X; Zhang X; Kam L; Chien N; Lai R; Cheung KS; Yuen MF; Cheung R; Seto WK; Nguyen MH
    Gut; 2024 Aug; ():. PubMed ID: 39122360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of metabolic dysfunction-associated steatotic liver disease in acute myocardial infarction: A propensity score-matched analysis.
    Kong G; Cao G; Koh J; Chan SP; Zhang A; Wong E; Chong B; Jauhari SM; Wang JW; Mehta A; Figtree GA; Mamas MA; Ng G; Chan KH; Chai P; Low AF; Lee CH; Yeo TC; Yip J; Foo R; Tan HC; Huang DQ; Muthiah M; Chan MY; Loh PH; Chew NWS
    Diabetes Obes Metab; 2024 Aug; 26(8):3328-3338. PubMed ID: 38779875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of MASLD with the risk of extrahepatic cancers: A systematic review and meta-analysis of 18 cohort studies.
    Zhou BG; Jiang X; She Q; Ding YB
    Eur J Clin Invest; 2024 Nov; 54(11):e14276. PubMed ID: 38943276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.
    Wang L; Xu R; Kaelber DC; Berger NA
    JAMA Netw Open; 2024 Jul; 7(7):e2421305. PubMed ID: 38967919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
    Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
    Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.